


PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 2791.1003-007		APPLICATION NO. 10/082,815	
SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION March 30, 2004 (Use several sheets if necessary)		FIRST NAMED INVENTOR Michael Sworin		FILING DATE February 22, 2002	
		EXAMINER C.D. Ly		CONFIRMATION NO. 1636	
				GROUP 1631	

U.S. PATENT DOCUMENTS				
EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
ca	AG2	2002/0031780 A1	03-14-2002	Way
	AH2	6,465,192 B2	10-15-2002	Way
	AJ2	2003/0003513 A1	01-02-2003	Way

EXAMINER <i>chur</i>	DATE CONSIDERED 5/27/04
-------------------------	----------------------------

PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION September 20, 2002 (Use several sheets if necessary)				ATTORNEY DOCKET NO. 2791.1003-007		APPLICATION NO. 10/082,815	
				APPLICANT Michael Sworin, et al.			
				FILING DATE February 22, 2002		GROUP 1645 1631	
U.S. PATENT DOCUMENTS							
EXAM- INER INI- TIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE	
COL	AA	5,474,911	Pontius	435	41		
	AB	5,612,034	Pouletty et al.	424	184.1		
	AC	5,698,401	Fesik et al.	435	7.1		
	AD	5,763,595	Gold et al.	536	2.1		
	AE	5,804,390	Fesik et al.	435	7.1		
	AF	5,843,440	Pouletty et al.	424	133.1		
	AG	5,891,643	Fesik et al.	435	7.1		
	AH	5,958,703	Dower et al.	435	7.1		
	AI	5,962,219	Gold et al.	435	6		
	AJ	5,989,827	Fesik et al.	435	7.1		
	AK	6,043,024	Fesik et al.	435	4		
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO	
COL	AL	WO 97/25074	PCT				
	AM	WO 97/29372	PCT				
	AN	WO 98/11437	PCT				
	AO	WO 98/19162	PCT				
	AP	WO 98/46270	PCT				
	AQ	WO 98/47002	PCT				
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
COL	AR	Way, J. C., "Covalent modification as a strategy to block protein-protein interactions with small-molecule drugs," <i>Current Opinion in Chemical Biology</i> , 4:40-46 (2000).					
	AS	Krantz, A., Diversification of the drug discovery process," <i>Nature Biotechnology</i> , Vol. 16:1294 (1998).					
	AT	Krantz, A., et al., "Drug Pharmacophores Covalently Linked to the Red Cell Surface are Active Without Prior Release. Drug Targeting of Renin with a Synthetic Ligand Conjugated to Red Blood Cells," <i>Journal of Drug Targeting</i> , 7(2):113-130 (1999).					
EXAMINER				DATE CONSIDERED			
				5/27/04			


PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION September 20, 2002 (Use several sheets if necessary)		ATTORNEY DOCKET NO. 2791.1003-007	APPLICATION NO. 10/082,815
APPLICANT Michael Sworin et al.		FILING DATE February 22, 2002	
GROUP 1645 1631			

U.S. PATENT DOCUMENTS							
EXAM- INER INI- TIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE	
CM	AA2	6,087,375	7/11/00	Bridon et al.	514	314	
	AB2	6,103,233	8/15/00	Pouletty et al.	424	133.1	
	AC2	6,107,489	8/22/00	Krantz et al.	548	338.1	
	AD2	5,705,337	1/6/98	Gold et al.	435	6	
	AE2						

FOREIGN PATENT DOCUMENTS							
DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO		
CM	AL2	WO 99/24074	20-5-00	PCT			
	AM2	WO 99/24076	20-5-99	PCT			
	AN2	WO 99/24462	20-5-99	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
CM	AU Krantz, A., "Red Cell-Mediated Therapy: Opportunities and Challenges," <i>Blood Cells, Molecules, and Diseases</i> , 23(3):58-68 (1997).
	AV Krantz, A., "Peptidyl (Acyloxy)methanes as Quiescent Affinity Labels for Cysteine Proteinases," <i>Methods in Enzymology</i> , 244:656-671 (1994).
	AW Weir, M. P., et al., "Novel Natural Product 5,5-trans-Lactone Inhibitors of Human α -Thrombin: Mechanism of Action and Structural Studies," <i>Biochemistry</i> , 37:6645-6657 (1998).
	AX Hemmerich, S., et al., "Identification of Residues in the Monocyte Chemotactic Protein-1 That Contact the MCP-1 Receptor, CCR2," <i>Biochemistry</i> , 38:13013-13025 (1999).
	AY Finch, H., et al., "5,5-TRANS LACTONE-CONTAINING INHIBITORS OF SERINE PROTEASES: IDENTIFICATION OF A NOVEL, ACYLATING THROMBIN INHIBITOR," <i>Bioorganic & Medicinal Chemistry Letters</i> , 8:2955-2960 (1998).
	AZ Montecarlo, F.S., et al., "The Amino-terminal Domain of CCR2 Is Both Necessary and Sufficient for High Affinity Binding of Monocyte Chemoattractant Protein 1," <i>The Journal of Biological Chemistry</i> , 272(37): 23186-23190 (1997).
	AR2 Tilley, J.W., et al., "Identification of a Small Molecule Inhibitor of the IL-2/IL-2R α Receptor Interaction Which Binds to IL-2," <i>J. Am. Chem. Soc.</i> , 119:7589-7590 (1997).

EXAMINER	DATE CONSIDERED 5/27/04
----------	-------------------------

PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION September 20, 2002 (Use several sheets if necessary)				ATTORNEY DOCKET NO. 2791.1003-007		APPLICATION NO. 10/082,815	
				APPLICANT Michael Sworin et al.			
				FILING DATE February 22, 2002		GROUP 2645 1631	
U.S. PATENT DOCUMENTS							
EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AF2						
	AG2						
	AH2						
	AI2						
	AJ2						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	AO2	WO 99/24075	20-6-99	PCT			
	AP2	WO 99/31265	24-6-99	PCT			
	AQ2	WO 99/48536	30-9-99	PCT			
	AL3	WO 99/64032	16-12-99	PCT			
	AM3	WO 99/64036	16-12-99	PCT			
	AN3	WO 99/66944	29-12-99	PCT			
	AO3	WO 00/00823	6-1-00	PCT			
	AP3	WO 00/39585	6-7-00	PCT			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AS2	Skelton, N. J., et al., "Structure of a CXC chemokine-receptor fragment in complex with interleukin-8," <i>Structure</i> 7(2):157-168 (1999).					
	AT2	Shuker, S.B., et al., "Discovering High-Affinity Ligands for Proteins: SAR by NMR," <i>Science</i> , 274:1531-1534 (1996).					
	AU2	Steitz, S.A., et al., "Mapping of MCP-1 functional domains by peptide analysis and site-directed mutagenesis," <i>FEBS Letters</i> , 430(158-164) (1998).					
	AV2	Reckless, J., et al., "Identification of oligopeptide sequences which inhibit migration induced by a wide range of chemokines," <i>Biochem. J.</i> , 340:803-811 (1999).					
	AW2	Spaldin, V., et al., "The effect of enzyme inhibition on the metabolism and activation of tacrine by human liver microsomes," <i>Br J Clin Pharmacol</i> , 38:15-22, (1994).					
EXAMINER 				DATE CONSIDERED 5/27/04			

PTO-1449 REPRODUCED <p style="text-align: center;">SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION</p> <p style="text-align: center;">September 24, 2002</p> <p style="text-align: center;">(Use several sheets if necessary)</p>	ATTORNEY DOCKET NO. 2791.1003-007	APPLICATION NO. 10/082,815
APPLICANT Michael Sworin, et al.		
FILING DATE February 22, 2002		GROUP 1645 1631

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
CAE	AE2	5,840,733	11/24/98	Krantz et al.	514	311
I	AF2	5,942,620	08/24/99	Krantz et al.	546	166

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
CAE AQ3 WO 99/40435	12-AUG-99	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER <i>ehw</i>	DATE CONSIDERED 5/27/04
---------------------	-------------------------

PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.
2791.1003-007

APPLICATION NO.
10/082,815

SUPPLEMENTAL
INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

APPLICANT
Michael Sworin, et al.

RECEIVED

September 24, 2002

FILING DATE
February 22, 2002

GROUP
1645

OCT 08 2002

(Use several sheets if necessary)

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AE2	5,840,733	11/24/98	Krantz et al.	514	311	
	AF2	5,942,620	08/24/99	Krantz et al.	546	166	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	AQ3	WO 99/40435	12-AUG-99	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER

DATE CONSIDERED